Pharmacopeia, Inc.
P.O. Box 5350
Princeton
New Jersey
08543-5350
United States
Tel: 609-452-3600
Fax: 609-452-3672
Website: http://www.pharmacopeia.com/
74 articles about Pharmacopeia, Inc.
-
Ligand Pharmaceuticals Inc. Completes Pharmacopeia, Inc. Acquisition
12/29/2008
-
Quantros Acquires MEDMARX(R) from United States Pharmacopeia, Inc.
12/9/2008
-
Pharmacopeia, Inc. to Request a Hearing With NASDAQ Following Receipt of Notice of Non-Compliance
11/10/2008
-
Pharmacopeia, Inc. Announces Third Quarter 2008 Financial Results
11/7/2008
-
Ligand Pharmaceuticals Inc. and Pharmacopeia, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
11/4/2008
-
Ligand Pharmaceuticals Inc. and Pharmacopeia, Inc. to Present At the Oppenheimer 19th Annual Healthcare Conference
10/29/2008
-
Pharmacopeia, Inc. Receives Notification From NASDAQ
10/3/2008
-
Ligand Pharmaceuticals Inc. to Acquire Pharmacopeia, Inc. for Stock and Contingent Value Rights for $70M
9/25/2008
-
Pharmacopeia, Inc. and GlaxoSmithKline Collaboration Identifies Sixth Lead Compound
9/16/2008
-
Pharmacopeia, Inc. to Present At the Canaccord Adams 28th Annual Global Growth Conference
7/30/2008
-
Pharmacopeia, Inc. Advances Therapeutic Program With GlaxoSmithKline
7/24/2008
-
Pharmacopeia, Inc. to Present At the BMO Capital Markets 8th Annual Focus On Healthcare Conference
7/23/2008
-
Pharmacopeia, Inc. to Host Second Quarter 2008 Financial Results Webcast and Conference Call
7/17/2008
-
Pharmacopeia, Inc. Receives Milestone Payment from GlaxoSmithKline as a Result of Lead Compound Identification
6/4/2008
-
Pharmacopeia, Inc. and GlaxoSmithKline Collaboration Identifies a New Lead Compound
6/4/2008
-
Pharmacopeia, Inc. to Cut Jobs, Sees Charge in Q2
5/30/2008
-
Pharmacopeia, Inc. Shares Rise On Blood Pressure Study; First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
5/16/2008
-
Pharmacopeia, Inc. Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
4/15/2008
-
Pharmacopeia, Inc. CEO Resigns
4/11/2008
-
Pharmacopeia, Inc. to Receive $5 Million Payment from GlaxoSmithKline
3/18/2008